Impact of Intensive Hypertension Management on Cardiovascular Outcomes in US Adults

Overview

This study generalized the SPRINT trial results to a US population of middle-aged and older adults with hypertension, estimating that intensive systolic blood pressure treatment (target <120 mm Hg) reduces cardiovascular events with a hazard ratio of 0.76 compared to standard treatment. The analysis found no significant increase in serious adverse events with intensive treatment, supporting its safety and efficacy in the broader target population.

Background

Hypertension affects a large proportion of US adults, increasing with age, and is a major risk factor for cardiovascular disease (CVD). While lowering blood pressure reduces CVD risk, the optimal systolic blood pressure target remains debated due to concerns about adverse events from intensive treatment, especially in older adults. The SPRINT trial demonstrated cardiovascular benefits of targeting SBP <120 mm Hg versus <140 mm Hg in adults aged 50 and older, but trial participants may not fully represent the general hypertensive population. This study aimed to generalize SPRINT findings to the broader US population eligible for intensive treatment.

Data Highlights

Key Findings

• The hazard ratio for cardiovascular events with intensive treatment was 0.76, consistent with the original SPRINT trial estimate of 0.73.
• The 5-year absolute risk reduction for cardiovascular events was approximately 2.2%, though confidence intervals included no effect.
• Serious adverse events did not increase significantly with intensive treatment (HR 0.97), indicating a similar safety profile.
• The target US population for intensive treatment differs demographically and clinically from SPRINT trial participants but experiences similar benefits.
• Intensive blood pressure management was achieved using various antihypertensive regimens, with lifestyle modifications encouraged.

Clinical Implications

Clinicians can consider intensive systolic blood pressure lowering to <120 mm Hg in eligible middle-aged and older adults with hypertension to reduce cardiovascular risk without a significant increase in serious adverse events. Patient selection should follow criteria similar to SPRINT eligibility, excluding those with diabetes or prior stroke. Monitoring for adverse events remains important, but intensive treatment appears safe and effective in a real-world US population.

Conclusion

Generalizing SPRINT trial results to the US hypertensive population supports the cardiovascular benefits and safety of intensive systolic blood pressure management. These findings reinforce current guidelines advocating for lower blood pressure targets in appropriate patients.

References

1. SPRINT Research Group/2015 -- A Randomized Trial of Intensive versus Standard Blood-Pressure Control
2. National Health and Nutrition Examination Survey (NHANES)/2011-2018 -- Population Data for Hypertension Analysis